Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro

被引:22
|
作者
Arul, Melanie [1 ]
Roslani, April Camilla [2 ]
Cheah, Swee Hung [1 ]
机构
[1] Univ Malaya, Fac Med, Dept Physiol, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Fac Med, Dept Surg, Kuala Lumpur 50603, Malaysia
关键词
Colorectal cancer; Fluorouracil; Oxaliplatin; Drug combination; Chou-Talalay; MULTICENTER RANDOMIZED-TRIAL; CIRCULATING TUMOR-CELLS; DOWN-REGULATION; PLATINUM RESISTANCE; 1ST-LINE TREATMENT; REPAIR PATHWAYS; PROSTATE-CANCER; GENE-EXPRESSION; BREAST-CANCER; KAPPA-B;
D O I
10.1007/s11626-016-0126-x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Tumor heterogeneity may give rise to differential responses to chemotherapy drugs. Therefore, unraveling tumor heterogeneity has an implication for biomarker discovery and cancer therapeutics. To test this phenomenon, we investigated the differential responses of three secondary colorectal cancer cell lines of different origins (HCT116, HT29, and SW620 cells) and four novel primary cell lines obtained from different colorectal cancer patients to 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) and explored the differences in gene expression among the primary cell lines in response to exposure to cytotoxic drugs. Cells were exposed to different doses of 5-FU and L-OHP separately or in combinations of equitoxic drug or equimolar drug ratios (median effect of Chou-Talalay principle). Cell viability was assessed using MTT assay and the respective IC50 values were determined. Changes in gene expression in primary cell lines after exposure to the same drug doses were compared using real-time PCR array. The sensitivities (IC50) of different cell lines, both secondary and primary, to 5-FU and L-OHP were significantly different, whether in monotherapy or combined treatment. Primary cell lines needed higher doses to reach IC50. There were variations in gene expression among the primary cell lines of different chemosensitivities to the challenge of the same combined dose of 5-FU and L-OHP. The results confirm the heterogeneous nature of colorectal cancer cells from different patient tumors. Studies using primary cancer cells established from patient's tumors rather than secondary cell lines will more closely reflect the actual character of the disease.
引用
收藏
页码:435 / 447
页数:13
相关论文
共 50 条
  • [41] In vitro study of radiosensitivity in colorectal cancer cell lines associated with Lynch syndrome
    Sun, Mingzhu
    Moquet, Jayne
    Barnard, Stephen
    Mancey, Hannah
    Burling, David
    Baldwin-Cleland, Rachel
    Monahan, Kevin
    Latchford, Andrew
    Lloyd, David
    Bouffler, Simon
    Badie, Christophe
    Anyamene, Nicola A.
    Ainsbury, Elizabeth
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [42] Differences in attitudes between patients with primary colorectal cancer and patients with secondary colorectal cancer: is it reflected in their willingness to participate in drug trials?
    Garcea, G
    Lloyd, T
    Steward, WP
    Dennison, AR
    Berry, DP
    EUROPEAN JOURNAL OF CANCER CARE, 2005, 14 (02) : 166 - 170
  • [43] Evolution of Adaptive Molecular Alterations and Drug Response in Patient Derived Primary Liver Cancer Cell Lines
    Castven, Darko
    Becker, Diana
    Czauderna, Carolin, II
    Wilhelm, Diana
    Andersen, Jesper B.
    Strand, Susanne
    Hartmann, Monika
    Heilmann-Heimbach, Stefanie
    Roth, Wilfried
    Hartmann, Nils
    Straub, Beate
    Mahn, Friederike
    Franck, Sophia
    Pereira, Sharon
    Haupts, Anna
    Vogel, Arndt
    Woerns, Marcus-Alexander
    Weinmann, Arndt
    Heinrich, Stefan
    Lang, Hauke
    Thorgeirsson, Snorri S.
    Galle, Peter R.
    Marquardt, Jens U.
    HEPATOLOGY, 2018, 68 : 878A - 879A
  • [44] Molecular analysis of drug response in short-term cultivated primary cells of colorectal cancer patients
    Sullivan, Kevin
    Spruessel, Annika
    Krueger, Jana
    Hennesen, Jana
    Spangenberg, Joerg
    Zornig, Carsten
    Juhl, Hartmut
    David, Kerstin
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3377S - 3378S
  • [45] PRIMARY AND SECONDARY PREVENTION OF COLORECTAL-CANCER
    HUGHES, II
    STELTER, B
    GARCIATORRES, FI
    BENTLIF, PS
    LEWIS, AM
    GASTROENTEROLOGY, 1988, 94 (05) : A196 - A196
  • [46] Primary and secondary prevention in sporadic colorectal cancer
    Thermann, P.
    Seufferlein, T.
    ONKOLOGE, 2009, 15 (12): : 1193 - +
  • [47] Metabolic heterogeneity of gastric cancer cell lines
    Xia-xia FAN
    Ying-li ZHU
    Bei-bei SHAO
    Lu-lu LI
    Ya-fei LI
    Ao JIA
    Ai-feng WANG
    Yong-cheng MA
    中国药理学与毒理学杂志, 2018, 32 (04) : 278 - 279
  • [48] IN VITRO MODELLING OF COLORECTAL CANCER CELL ARREST IN THE HEPATIC SINUSOIDS: CANCER CELL INTERACTIONS WITH KUPFFER CELLS AND SINUSOIDAL ENDOTHELIAL CELLS IN COLORECTAL CANCER LIVER METASTASIS
    Paschos, Konstantinos A.
    Majeed, Ali W.
    Bird, Nigel C.
    ANTICANCER RESEARCH, 2014, 34 (10) : 6104 - 6105
  • [49] Characterization of novel low passage primary and metastatic colorectal cancer cell lines
    Boot, Arnoud
    van Eendenburg, Jaap
    Crobach, Stijn
    Ruano, Dina
    Speetjens, Frank
    Calame, Jan
    Oosting, Jan
    Morreau, Hans
    van Wezel, Tom
    ONCOTARGET, 2016, 7 (12) : 14499 - 14509
  • [50] TRAIL in primary gastric epithelial cells, in gastric cancer cell lines and in gastric cancer
    Bauer, H
    Stremmel, W
    Wagner, S
    Rudi, J
    GUT, 2001, 49 : A3 - A3